🌍·12h agodiscovery
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
Publisher
T
The Manila Times
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- The Manila Times
- Region
- Global
- Scope
- discovery
- Published
- August 6, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: The Manila Times
Scope: discovery
Related coverage
More related coverage
Pharmaceutical Executive/3h ago
Mergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumors
fiercebiotech.com/3h ago
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
koreabiomed.com/3h ago
Onconic’s GERD drug Jaqbo wins first overseas approval in India
pharmaphorum/3h ago